Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) have received an average recommendation of “Hold” from the twenty-three ratings firms that are currently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating, four have given a buy rating and one has issued a strong buy rating on the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $388.80.

A number of brokerages recently commented on REGN. BidaskClub downgraded shares of Regeneron Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, March 16th. Jefferies Financial Group lowered their price target on shares of Regeneron Pharmaceuticals from $376.00 to $343.00 and set a “hold” rating for the company in a report on Wednesday, April 17th. BMO Capital Markets lowered their price target on shares of Regeneron Pharmaceuticals from $412.00 to $375.00 and set a “market perform” rating for the company in a report on Wednesday, May 8th. Canaccord Genuity reaffirmed a “hold” rating and issued a $353.00 price target (down previously from $408.00) on shares of Regeneron Pharmaceuticals in a report on Wednesday, May 8th. Finally, Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $420.00 to $389.00 and set an “equal weight” rating for the company in a report on Wednesday, May 8th.

Shares of NASDAQ:REGN traded up $2.86 during trading on Friday, reaching $318.39. The company’s stock had a trading volume of 545,044 shares, compared to its average volume of 865,411. The company has a quick ratio of 3.78, a current ratio of 4.58 and a debt-to-equity ratio of 0.08. Regeneron Pharmaceuticals has a 12 month low of $295.27 and a 12 month high of $442.00. The company’s 50 day moving average price is $309.16. The stock has a market cap of $34.79 billion, a PE ratio of 16.08, a PEG ratio of 1.48 and a beta of 1.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported $4.45 EPS for the quarter, missing the Zacks’ consensus estimate of $5.24 by ($0.79). Regeneron Pharmaceuticals had a net margin of 35.13% and a return on equity of 26.95%. The business had revenue of $1.71 billion during the quarter, compared to the consensus estimate of $1.76 billion. During the same period in the previous year, the business posted $4.67 EPS. The firm’s revenue was up 13.3% on a year-over-year basis. On average, equities analysts predict that Regeneron Pharmaceuticals will post 18.37 EPS for the current fiscal year.

In other news, EVP Neil Stahl sold 9,853 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $305.74, for a total transaction of $3,012,456.22. Following the completion of the sale, the executive vice president now owns 47,450 shares of the company’s stock, valued at $14,507,363. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Joseph L. Goldstein sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $305.93, for a total transaction of $305,930.00. Following the sale, the director now directly owns 11,323 shares of the company’s stock, valued at approximately $3,464,045.39. The disclosure for this sale can be found here. 11.84% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its stake in shares of Regeneron Pharmaceuticals by 1.9% during the first quarter. BlackRock Inc. now owns 6,042,908 shares of the biopharmaceutical company’s stock valued at $2,481,339,000 after acquiring an additional 113,683 shares in the last quarter. FMR LLC increased its holdings in Regeneron Pharmaceuticals by 6.6% during the fourth quarter. FMR LLC now owns 5,347,376 shares of the biopharmaceutical company’s stock valued at $1,997,245,000 after buying an additional 330,875 shares during the period. Geode Capital Management LLC increased its holdings in Regeneron Pharmaceuticals by 7.8% during the fourth quarter. Geode Capital Management LLC now owns 1,078,453 shares of the biopharmaceutical company’s stock valued at $402,138,000 after buying an additional 78,143 shares during the period. American Century Companies Inc. increased its holdings in Regeneron Pharmaceuticals by 3.7% during the first quarter. American Century Companies Inc. now owns 1,041,044 shares of the biopharmaceutical company’s stock valued at $427,473,000 after buying an additional 37,573 shares during the period. Finally, Northern Trust Corp increased its holdings in Regeneron Pharmaceuticals by 2.1% during the first quarter. Northern Trust Corp now owns 972,988 shares of the biopharmaceutical company’s stock valued at $399,528,000 after buying an additional 20,218 shares during the period. 66.91% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating various medical conditions worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: What is a capital gain?

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.



Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *